Literature DB >> 22547606

Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be proven.

Angelo Di Leo, Luca Malorni.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22547606     DOI： 10.1200/JCO.2012.41.7394

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

Review 1.  Challenges in the management of advanced, ER-positive, HER2-negative breast cancer.

Authors:  Christopher D Hart; Ilenia Migliaccio; Luca Malorni; Cristina Guarducci; Laura Biganzoli; Angelo Di Leo
Journal:  Nat Rev Clin Oncol       Date:  2015-05-26       Impact factor: 66.675

Review 2.  Breast cancer metastasis: issues for the personalization of its prevention and treatment.

Authors:  Natascia Marino; Stephan Woditschka; L Tiffany Reed; Joji Nakayama; Musa Mayer; Maria Wetzel; Patricia S Steeg
Journal:  Am J Pathol       Date:  2013-07-26       Impact factor: 4.307

Review 3.  Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers.

Authors:  Ilenia Migliaccio; Luca Malorni; Christopher D Hart; Cristina Guarducci; Angelo Di Leo
Journal:  BMC Med       Date:  2015-03-05       Impact factor: 8.775

4.  Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.

Authors:  Angelo Di Leo; Guy Jerusalem; Lubos Petruzelka; Roberto Torres; Igor N Bondarenko; Rustem Khasanov; Didier Verhoeven; José L Pedrini; Iya Smirnova; Mikhail R Lichinitser; Kelly Pendergrass; Luca Malorni; Sally Garnett; Yuri Rukazenkov; Miguel Martin
Journal:  J Natl Cancer Inst       Date:  2013-12-07       Impact factor: 13.506

5.  Aurora-A mitotic kinase induces endocrine resistance through down-regulation of ERα expression in initially ERα+ breast cancer cells.

Authors:  Mateusz Opyrchal; Jeffrey L Salisbury; Shuya Zhang; James McCubrey; John Hawse; Mattew P Goetz; Gwen A Lomberk; Tufia Haddad; Amy Degnim; Carol Lange; James N Ingle; Evanthia Galanis; Antonino B D'Assoro
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.